Marta López‐Parra

2.4k total citations
22 papers, 1.8k citations indexed

About

Marta López‐Parra is a scholar working on Epidemiology, Biochemistry and Hepatology. According to data from OpenAlex, Marta López‐Parra has authored 22 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 9 papers in Biochemistry and 9 papers in Hepatology. Recurrent topics in Marta López‐Parra's work include Liver Disease Diagnosis and Treatment (9 papers), Eicosanoids and Hypertension Pharmacology (9 papers) and Inflammatory mediators and NSAID effects (7 papers). Marta López‐Parra is often cited by papers focused on Liver Disease Diagnosis and Treatment (9 papers), Eicosanoids and Hypertension Pharmacology (9 papers) and Inflammatory mediators and NSAID effects (7 papers). Marta López‐Parra collaborates with scholars based in Spain, United States and Poland. Marta López‐Parra's co-authors include Joan Clària, Vicente Arroyo, Esther Titos, Ana González‐Périz, Marcos Martínez‐Clemente, Raquel Horrillo, Eva Morán‐Salvador, Natàlia Ferré, Anna Planagumà and Karsten Gronert and has published in prestigious journals such as The Journal of Immunology, Hepatology and The FASEB Journal.

In The Last Decade

Marta López‐Parra

22 papers receiving 1.8k citations

Peers

Countries citing papers authored by Marta López‐Parra

Since Specialization

Citations

This map shows the geographic impact of Marta López‐Parra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta López‐Parra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta López‐Parra more than expected).

Fields of papers citing papers by Marta López‐Parra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta López‐Parra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta López‐Parra. The network helps show where Marta López‐Parra may publish in the future.

Co-authorship network of co-authors of Marta López‐Parra

This figure shows the co-authorship network connecting the top 25 collaborators of Marta López‐Parra. A scholar is included among the top collaborators of Marta López‐Parra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta López‐Parra. Marta López‐Parra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Role for PPARγ in obesity‐induced hepatic steatosis as determined by hepatocyte‐ and macrophage‐specific conditional knockouts	The FASEB Journal	Eva Morán‐Salvador, Marta López‐Parra et al.	333
2	5-Lipoxygenase Activating Protein Signals Adipose Tissue Inflammation and Lipid Dysfunction in Experimental Obesity	The Journal of Immunology	Raquel Horrillo, Ana González‐Périz et al.	129
3	Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase	Prostaglandins & Other Lipid Mediators	Esther Titos, Natàlia Ferré et al.	21
4	80 ROLE FOR PPAR γ IN HEPATIC STEATOSIS AS DETERMINED BY HEPATOCYTE AND KUPFFER CELL-SPECIFIC CONDITIONAL KNOCKOUTS USING CRE RECOMBINASE	Journal of Hepatology	Eva Morán‐Salvador, Marta López‐Parra et al.	9
5	5-Lipoxygenase Deficiency Reduces Hepatic Inflammation and Tumor Necrosis Factor α–Induced Hepatocyte Damage in Hyperlipidemia-Prone Apoe-Null Mice	Hepatology	Marcos Martínez‐Clemente, Natàlia Ferré et al.	90
6	Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols	American Journal of Physiology-Gastrointestinal and Liver Physiology	Natàlia Ferré, Marcos Martínez‐Clemente et al.	64
7	Obesity‐induced insulin resistance and hepatic steatosis are alleviated by ω‐3 fatty acids: a role for resolvins and protectins	The FASEB Journal	Ana González‐Périz, Raquel Horrillo et al.	475
8	Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice	Journal of Lipid Research	Marta López‐Parra, Esther Titos et al.	45
9	Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor	Journal of Pharmacology and Experimental Therapeutics	Raquel Horrillo, Anna Planagumà et al.	48
10	Gene expression profiling of renal dysfunction in rats with experimental cirrhosis	Journal of Hepatology	Marta López‐Parra, Esther Titos et al.	3
11	Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells	Journal of Leukocyte Biology	Esther Titos, Joan Clària et al.	51
12	Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites†	Hepatology	Joan Clària, Jeffrey D. Kent et al.	58
13	The selective cyclooxygenase‐2 inhibitor SC‐236 reduces liver fibrosis by mechanisms involving non‐parenchymal cell apoptosis and PPARγ activation	The FASEB Journal	Anna Planagumà, Joan Clària et al.	114
14	New Perspectives in the Modulation of the Eicosanoid Cascade in Inflammation	Letters in Drug Design & Discovery	Joan Clària, Marta López‐Parra	3
15	The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARγ. Influence of albumin	Journal of Hepatology	Marta López‐Parra, Joan Clària et al.	17
16	21 The selective cyclooxygenase-2 inhibitor SC-236 reduces experimental liver fibrosis by inactivating kupffer cells and acting as a peroxisome proliferator-activated receptor gamma ligand	Journal of Hepatology	Anna Planagumà, Joan Clària et al.	1
17	Inhibition of 5‐lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis	The FASEB Journal	Esther Titos, Joan Clària et al.	65
18	Cyclooxygenase‐1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites	British Journal of Pharmacology	Marta López‐Parra, Joan Clària et al.	35
19	Aspirin (ASA) regulates 5‐lipoxygenase activity and peroxisome proliferator‐activated receptor α‐mediated CINC‐1 release in rat liver cells: novel actions of lipoxin A ₄ (LXA ₄ ) and ASA‐triggered 15‐epi‐LXA ₄	The FASEB Journal	Anna Planagumà, Esther Titos et al.	45
20	5-lipoxygenase (5-LO) is involved in Kupffer cell survival	Journal of Hepatology	Esther Titos, Joan Clària et al.	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact